Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanbongi, Y. Articles by Ubukata, K. Search for Related Content PubMed PubMed Citation Articles by Sanbongi, Y. Articles by Ubukata, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2006, p. 2487-2492, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.01316-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Molecular Evolution of ß-Lactam-Resistant Haemophilus influenzae: 9-Year Surveillance of Penicillin-Binding Protein 3 Mutations in Isolates from Japan

Yumiko Sanbongi,¹ Takahisa Suzuki,¹ Yumi Osaki,¹ Nami Senju,¹ Takashi Ida,^1* and Kimiko Ubukata²

Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567,¹ Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences & Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan²

Received 7 October 2005/ Returned for modification 23 December 2005/ Accepted 23 April 2006

Top Abstract Introduction Materials and Methods Results Discussion References

 
A total of 621 clinical isolates of Haemophilus influenzae collected in Japan between 1995 and 2003 were studied for their susceptibilities to several antimicrobial agents, ß-lactamase production, and amino acid substitutions in penicillin-binding protein 3 (PBP 3). Over the four study periods (first period, 1995 to 1996; second period, 1997 to 1998; third period, 2000 to 2001; fourth period, 2002 to 2003), the susceptibilities to ß-lactam agents decreased and the incidence of isolates with substitutions at positions 377, 385, 389, 517, and/or 526 in PBP 3 increased from 28.8% to 52.0%. Five hundred seventy-one ß-lactamase-nonproducing isolates were grouped into 18 classes, based on the pattern of the five mutations in PBP 3. The Asp526Lys substitution led to 6.0-, 4.3-, 2.4-, and 5.4-fold increases in amoxicillin-clavulanic acid, cefdinir, cefditoren, and faropenem resistance, respectively. PBP 3 with multiple substitutions (Met377Ile, Ser385Thr, and/or Leu389Phe) together with Asp526Lys resulted in increased resistance compared to that for PBP 3 with the Asp526Lys substitution alone. These results indicate that mutations at these five positions increased resistance to most ß-lactams. Although a significant change in the prevalence of ß-lactamase-producing strains was not observed, the proportions of those possessing both PBP 3 alterations and ß-lactamase production have slightly increased (from 1.4% to 5.0%). The ROB-1 ß-lactamase was rare, but this is the first report of this ß-lactamase in Japan.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Haemophilus influenzae is an important pathogen that causes community-acquired infections such as pneumonia, otitis media, and meningitis and has become increasingly resistant to ß-lactam antibiotics (5, 18). There are two major mechanisms involved in ß-lactam resistance, one enzymatic and the other nonenzymatic. The enzymatic resistance mechanism is mainly mediated by the hydrolysis of ß-lactams due to the production of TEM-1 ß-lactamase (17, 24) and, in some cases, to a ROB-1 ß-lactamase (10, 13). The nonenzymatic mechanism involves a decreased affinity of penicillin-binding protein 3 (PBP 3) for ß-lactam antibiotics due to amino acid substitutions (17, 23). The ß-lactam resistance phenotype mediated by the nonenzymatic mechanism is called "ß-lactamase-nonproducing ampicillin resistance (BLNAR)" in H. influenzae.

Recently, the isolation frequency of BLNAR strains has been increasing exponentially among clinical isolates from patients with community-acquired infections in Japan (21, 25). A recent report also described an increased prevalence of the BLNAR phenotype in Europe (4). Strains with both resistance mechanisms were also found among clinical isolates, and such strains are termed ß-lactamase-producing ampicillin-clavulanic acid-resistant (BLPACR) H. influenzae (6, 12, 22).

Studies of ß-lactam resistance caused by H. influenzae PBP 3 mutations have been reported by several investigators (1, 6, 16, 20, 23). From the genetic analysis of the ftsI gene encoding PBP 3 in BLNAR strains, the amino acid substitutions surrounding the conserved KTG (Lys512-Thr-Gly) and SSN (Ser379-Ser-Asn) motifs appear to be responsible for ß-lactam resistance. Amino acid substitutions, including asparagine to lysine at position 526 (N526K) or arginine to histidine at position 517 (R517H), near the KTG motif, were commonly found in isolates with intermediate resistance (MICs, 0.063 to 0.25 µg/ml) to cefotaxime. Additional amino acid substitutions near the SSN motif, such as methionine to isoleucine at position 377 (M377I), serine to threonine at position 385 (S385T), and/or leucine to phenylalanine at position 389 (L389F), were frequently found in isolates with higher levels of resistance (MICs, 1 to 2 µg/ml) to cefotaxime.

Although the mechanisms of resistance have been revealed in BLNAR strains, the evolution of BLNAR strains has not been clarified. The aim of this study is to clarify the molecular change of PBP 3 amino acid substitutions and ß-lactam susceptibilities in clinical isolates. Therefore, we collected a total of 621 clinical isolates between 1995 and 2003 from several Japanese hospitals and investigated the amino acid substitutions in PBP 3 and their correlation with ß-lactam susceptibilities.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Bacterial strains. A total of 621 clinical isolates were collected between 1995 and 2003 from 122 hospitals in different parts of Japan or from a working group in Japan that collected strains for a postmarketing surveillance of cefditoren-pivoxil (11). Most strains (>95%) were isolated from patients with community-acquired respiratory tract infections, such as pneumonia, bronchitis, otitis media, pharyngitis, and sinusitis, in various medical settings. There were only a few isolates from patients with bacteremia, meningitis, and conjunctivitis. These isolates were divided into four groups on the basis of isolation periods. The numbers of isolates tested were 73 for the first period (1995 to 1996), 119 for the second period (1997 to 1998), 229 for the third period (2000 to 2001), and 200 for the fourth period (2002 to 2003). In order to identify the isolates as H. influenzae, all isolates were tested for the requirement of ß-NAD (V factor) and hemin (X factor). The production of ß-lactamase was detected by the P/Case test (Nissui Seiyaku Co., Ltd. Tokyo Japan), which is one of the modified acidimetry methods.

Antimicrobial susceptibility testing. MICs were determined by the microdilution method recommended by the Clinical and Laboratory Standards Institute (14). For the MIC tests, the prepared medium, which was Mueller-Hinton II broth (Becton Dickinson Company, Sparks, MD) supplemented with 2% defibrinated, heat-treated horse blood plus 15 µg/ml ß-NAD, was obtained from Eiken Chemical Co., Ltd. (Tokyo Japan). The antibiotics tested were as follows: ampicillin, amoxicillin-clavulanic acid, piperacillin-tazobactam, cefotiam, ceftazidime, cefotaxime, ceftriaxone, cefaclor, cefpodoxime, cefdinir, cefditoren, faropenem, imipenem, meropenem, azithromycin, and levofloxacin.

PCR and nucleotide sequencing. We determined the DNA sequences of the ftsI gene encoding PBP 3 for the 621 H. influenzae isolates. The full-length ftsI gene was amplified by PCR with Ex Taq polymerase (Takara Shuzo Co., Ltd., Kyoto, Japan). The primers used for DNA amplification and sequencing were originally designed on the basis of the DNA sequences of the Rd strain (3) (DDBJ/EMBL/GenBank accession number NC000907), as follows: 5'-CTCGTTATCCGTTACAGCAG-3' for the sense primer and 5'-GCCAAACCGTGTGATGAAAC-3' for the antisense primer. PCR amplification was performed with a PCR system 9700 (Applied Biosystems, Foster City, CA), as follows: 2 min of denaturation at 98°C and 30 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 3 min. Both strands of the amplified DNA fragments were sequenced by using an Applied Biosystems 3730 DNA analyzer. The deduced amino acid substitutions in PBP 3 of the strains tested were compared with the amino acid sequence of PBP 3 from the Rd strain. The carriage of TEM-1 and ROB-1 ß-lactamase genes was investigated by PCR with the following primer sets: 5'-ACCAGTCACAGAAAAGCATC-3' and 5'-TTATCCGCCTCCATCCAGTC-3' for bla_TEM-1 and 5'-TCCCGAAACCCAAAAATACG-3' and 5'-GATTGCCTGTTGCGTTATTG-3' for bla_ROB-1. The same amplification program described above was used.

Nucleotide sequence accession numbers. The sequences of the penicillin-binding protein 3 genes from five clinical isolates appear in the DDBJ/EMBL/GenBank nucleotide sequence databases. The corresponding accession numbers of the five clinical isolates in the DDBJ/ENBL/GenBank databases are as follows: AB257096 for strain MSC07237, AB257097 for strain MSC02023, AB257098 for strain MSC02104, AB257099 for strain MSC02149, and AB257100 for strain MSC02169.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Trends in antibiotic susceptibilities. The changes in the susceptibilities of the H. influenzae isolates during the four study periods are shown in Table 1. The geometric mean MICs of almost all ß-lactam antibiotics increased during the study period. In particular, the MIC₉₀s of some cephalosporins such as cefotiam, cefotaxime, ceftriaxone, and cefpodoxime were increased more than 16-fold from the first to the fourth period. Isolates resistant to high levels (>16 µg/ml) of cefotiam, cefaclor, and cefdinir have appeared since the second period. In contrast, a decrease in susceptibility to ceftazidime was not observed during the four study periods. The susceptibilities to carbapenems and faropenem also decreased over the four periods, but the decreases in susceptibilities were smaller than those for cephalosporins, with the exception of ceftazidime. The susceptibilities to amoxicillin-clavulanic acid showed decreases similar to those to cefdinir. However, the susceptibility to piperacillin-tazobactam did not decrease significantly. For the non-ß-lactam agents azithromycin and levofloxacin, no change in the MICs occurred.

View this table: [in this window] [in a new window]

TABLE 1. Trends in ß-lactam susceptibilities

Frequency of ß-lactamase-producing isolates. The isolation frequencies of ß-lactamase-producing H. influenzae isolates for the four periods are shown in Table 2. The incidences of ß-lactamase-producing isolates were 6.8, 14.2, 5.2, and 8.0% for the first, second, third, and fourth periods, respectively. Only one strain was positive for the ROB-1 ß-lactamase gene, while all others carried a TEM-1 ß-lactamase gene.

View this table: [in this window] [in a new window]

TABLE 2. Frequencies of isolation of ß-lactamase-producing strains

Molecular survey of amino acid substitutions in PBP 3. Amino acid substitutions in PBP 3 at positions 377, 385, 389, 517, and 526 have been found to be responsible for ß-lactam resistance. The frequencies of isolates carrying these mutant PBP 3s are shown in Table 3. No new amino acid substitutions were detected at positions 377, 385, 389, and 517; however, at position 526, one strain had a histidine and not a lysine in place of the asparagine.

View this table: [in this window] [in a new window]

TABLE 3. PBP 3 mutations and frequencies of isolation from clinical isolates

For the ß-lactamase-nonproducing isolates, the ratio of those without any of the amino acid substitutions listed above steadily declined during the surveillance period (first period, 65.8%; second period, 53.8%; third period, 47.6%; and fourth period, 45.0%). Although the prevalence of isolates with the R517H substitution decreased from 12.3 to 3.5% from the first to the fourth period, the appearance of isolates with the M377I, S385T, and/or L389F substitution, in addition to the R517H substitution, was observed since the third period. No remarkable change was observed in the frequencies of isolates with the N526K substitution during the four observational periods (12.3 to 18.3%). The isolates with the M377I, S385T, and L389F substitutions, in addition to the N526K substitution, increased as follows during the four study periods: 0, 5.0, 7.9, and 16.5%, respectively. Amino acid substitutions in PBP 3 were rarely seen (total, 1.4%) in the ß-lactamase-producing strains in the first period. By the fourth period, however, the incidence of those isolates had increased to 5.0%.

Amino acid substitutions in PBP 3 and ß-lactam resistance. To investigate the correlation between amino acid substitutions and resistance to ß-lactam antibiotics without bias from ß-lactamases, 571 ß-lactamase-nonproducing isolates were chosen and grouped into 18 classes, based on the pattern of the five mutations in PBP 3. Of the 18 classes, 11 did not contain a sufficient number of isolates for significant evaluation. For the seven major classes (number of isolates in each class, >10), the relationship between amino acid substitutions and ß-lactam resistance is indicated in Table 4. The M377I substitution (classified as group II) did not result in increased resistance to ß-lactams except piperacillin-tazobactam. For the group III isolates with the R517H substitution, the levels of resistance to penicillins and cephalosporins increased 1.7- to 4.3-fold compared with those for the nonmutated group I strains. Addition of the M377I and S385T substitutions (group IV) led to further increases in resistance, particularly to cefpodoxime (17.5-fold), cefotiam (11.7-fold), and cefdinir (11.4-fold). In contrast, resistance to imipenem and meropenem hardly increased for the group III and IV clinical isolates. For the N526K substitution (group V), the levels of resistance to all ß-lactams except ceftazidime increased 2.3- to 7.4-fold compared with those of the group I isolates. Addition of the S385T substitution (group VI) led to further increases (1.7- to 7.5-fold compared with group V) in resistance to all ß-lactams, including ceftazidime. Further addition of the M377I and L398F substitutions (group VII) resulted in high-level resistance (geometric mean MIC, >10 µg/ml) to amoxicillin-clavulanic acid, cefotiam, cefaclor, and cefdinir. Although the geometric mean MICs for cefotaxime and ceftriaxone for the group VII isolates were less than 1 µg/ml, the increases in resistance were 58.3- and 44.5-fold, respectively, compared with those for the group I isolates. Resistance to piperacillin-tazobactam, imipenem, and meropenem was not affected by the addition of M377I, S385T, and L389F substitutions in the N526K background (the increases in the ratios were less than 1.8-fold).

View this table: [in this window] [in a new window]

TABLE 4. Amino acid substitutions in PBP 3 and ß-lactam susceptibilities

ftsI gene sequence comparisons. In this study, it became apparent that several BLNAR isolates carried the ftsI gene with the same nucleotide mutations. The genetic composition of the ftsI gene, especially in five isolates with the M377I, S385T, and L389F substitutions, was of particular interest. The homology of the ftsI genes between these isolates and the Rd control strain is shown in Table 5.

View this table: [in this window] [in a new window]

TABLE 5. Percent identities of the nucleotide sequences of the ftsI gene between strain Rd and clinical isolates

The MSC02023 and MSC02169 isolates had the R517H substitution but not the N526K substitution, and the ftsI gene sequences were identical. On the other hand, strains MSC07237, MSC02104, and MSC02149 had the N526K substitution but not the R517H substitution, and the ftsI gene sequences were also identical between them. Although the degree of identity of the DNA sequence of the 3' end (nucleotide positions 1188 to 1833), including the region encoding the R517H and N526K substitutions, was 96.4%, the DNA sequences of their 5' ends (nucleotide positions 1 to 1187), including the region encoding the M377I, S385T, and L389F substitutions, were identical.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Over the four study periods, between 1995 and 2003, the prevalence of ß-lactam resistance has increased among clinical H. influenzae isolates in Japan. In this study, we characterized ß-lactamase production and identified the PBP 3 mutations in the resistant isolates. Based on our results, the number of ß-lactamase-positive isolates remained stable (between 5.2% and 14.3%), and these percentages were equivalent to those in Europe but lower than those in the United States (4, 8, 9). Most of the ß-lactamase-positive isolates carried a bla_TEM-1 gene and were resistant to ampicillin (>8 µg/ml). Only one ROB-1-producing isolate was observed, which represents the first ROB-1-positive H. influenzae isolate from Japan.

Isolates with the N526K substitution in PBP 3 steadily increased during the four study periods. In particular, those with additional M377I, S385T, and L389F substitutions, in addition to N526K, were observed since the second period and increased from 5.8% to 18.5%. Of the 62 isolates with these four substitutions, 53 (85.5%) showed MICs of >4 µg/ml for ampicillin or >8 µg/ml for amoxicillin-clavulanic acid, and most of them also had decreased susceptibilities to cephalosporins and carbapenems. On the other hand, the frequencies of isolates with the R517H substitution steadily declined over the four study periods. However, isolates with R517H and additional substitutions appeared in the third period. We compared the DNA sequences of the ftsI genes for five isolates with the M377I, S385T, and L389F substitutions, in addition to the R517H or N526K substitution (Table 5). Interestingly, the sequences of the 5' end of the gene were identical, while those at the 3' end of the gene were not. Furthermore, these isolates did not appear before the second study period. Several investigators reported that the horizontal transfer of the ompP2 gene between strains of H. influenzae occurred in patients (7, 19). Therefore, it is possible that the prevalence of isolates with the M377I, S385T, and L389F substitutions may be due to the horizontal transfer of the mutated ftsI gene. The genetic mechanism of BLNAR in H. influenzae may be the same as that in penicillin-resistant Streptococcus pneumoniae (2).

The isolates possessing both a PBP 3 alteration and ß-lactamase production as resistance mechanisms, which show the BLPACR phenotype, were still rare, and the levels of resistance to ß-lactams for these isolates were equivalent to those of isolates with the N526K substitution and additional M377I, S385T, and L389F substitutions. However, the incidence of isolates possessing the R517H or N526K substitution together with ß-lactamase production slightly increased, from 1.4% in the first period to 5.0% in the fourth period.

The increase in the numbers of ß-lactam-resistant strains of H. influenzae in Japan today is consistent with the spread of strains with the N526K or R517H substitution together with additional M377I, S385T, and L389F substitutions. The frequencies of isolates with these substitutions were very high compared with the situation in the United States and European countries (4, 8, 9). However, the levels of decreasing susceptibilities over the four study periods differed for the different ß-lactam agents. Therefore, piperacillin-tazobactam and ceftazidime were unique, in that increases in resistance to them appeared to be so small compared with those for the other beta-lactams. In contrast, high-level resistance to cefotiam, cefpodoxime, cefotaxime, and ceftriaxone was remarkably frequent. For such reasons, we have reviewed the relationship between amino acid substitutions in PBP 3 and resistance to each ß-lactam agent. The antimicrobial activities of piperacillin-tazobactam and ceftazidime were unaffected by the N526K substitution and additional M377I, S385T, and L389F substitutions compared with their effects on other cephalosporins and penicillins. It is interesting that resistance to piperacillin-tazobactam and ceftazidime was strongly influenced by the M377I and the R517H substitutions, respectively. These results suggest that piperacillin and ceftazidime might differ from other ß-lactams in their interactions with the mutated PBP 3 binding pockets. With ceftazidime, we think that the carboxypropoxyimino side chain at the C-7 position might play a role in the unique interaction.

The influence of amino acid substitutions on the activities of the carbapenems was also different from that on the activities of the cephalosporins. Imipenem and meropenem were affected by the N526K substitution and additional substitutions, but were hardly affected by the R517K substitution and additional substitutions. In our previous study with recombinants of the Rd strain carrying a mutated ftsI gene, resistance to carbapenems could not be explained solely by the five amino acid substitutions in PBP 3 (16). In this study, we found two novel amino acid substitutions near the conserved motifs: valine to isoleucine or alanine at position 329 (V329I/A) in the conserved Ser327-Thr-Val-Lys motif in five isolates and valine to alanine at position 511 (V511A) near the KTG motif in six isolates. However, these amino acid substitutions may not be responsible for carbapenem resistance (data not shown). We also found several isolates with atypical amino acid substitutions at positions 517 and 526. For those with both the R517H and the N526K substitutions, the levels of susceptibility to imipenem (MICs, 0.25 to 1 µg/ml) were comparable to those for isolates with the R517H substitution. This finding suggests that high-level resistance would not result even if the R517H and the N526K substitutions overlapped. Another mutant had a histidine instead of a lysine substitution at position 526 (N526H), in addition to ß-lactamase production. This isolate showed a slightly lower imipenem MIC compared with those for N526K strains and ß-lactamase production (data not shown).

In Japan, the expanded-spectrum oral cephalosporins and amoxicillin-clavulanic acid have commonly been used to treat community-acquired respiratory tract infections caused by H. influenzae and S. pneumoniae. The recent prevalence of the strains carrying the mutated ftsI gene may be attributed to the frequent use of these agents. Compared to the ß-lactams, levofloxacin, one of the fluoroquinolones, still shows potent activity against H. influenzae, including ß-lactam-resistant strains (Table 1). However, a recent report described the outbreak of fluoroquinolone-resistant H. influenzae that had been associated with the clinical use of levofloxacin (15). Additional measures should be taken in order to ensure that oral ß-lactam antibiotics continue to work against BLNAR strains. From the results of this study, we found that susceptibility to cefditoren was not much affected by amino acid substitutions that accumulated in PBP 3, and among the oral ß-lactams tested, this antibiotic showed the most potent activity against H. influenzae strains, including the BLNAR strains (Table 4). The reason why cefditoren worked against the BLNAR strains is not clear, but we propose that the C-3 methylthiazole side chain of cefditoren may be responsible for a different binding interaction with the mutated PBP 3s.

In summary, our study confirms the problematic prevalence of ß-lactam-resistant strains of H. influenzae in Japan. The increase in the numbers of these isolates correlated well with the spread of strains with PBP 3 mutations. Amino acid substitutions, such as N526K or R517H, together with additional M377I, S385T, and L389F substitutions, in PBP 3 brought about reduced susceptibilities to most of the ß-lactam agents tested. However, piperacillin-tazobactam, ceftazidime, and carbapenems were not as strongly affected by these mutations.

 
We thank the Community-Acquired Bacterial Infections Working Group in Japan, in cooperation with Meiji Seika Kaisha, Ltd., for kindly providing clinical isolates of H. influenzae.

 
* Corresponding author. Mailing address: Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan. Phone: 81-45-541-2521. Fax: 81-45-543-9771. E-mail: takashi_ida{at}meiji.co.jp.

Top Abstract Introduction Materials and Methods Results Discussion References

 

1
1. Dabernat, H., C. Delmas, M. Seguy, R. Pelissier, G. Faucon, S. Bennamani, and C. Pasquier. 2002. Diversity of ß-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob. Agents Chemother. 46:2208-2218.[Abstract/Free Full Text]
2
2. Dowson, C. G., A. Hutchison, J. A. Brannigan, R. C. George, D. Hansman, J. Linares, A. Tomasz, J. M. Smith, and B. G. Spratt. 1989. Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc. Natl. Acad. Sci. USA 86:8842-8846.[Abstract/Free Full Text]
3
3. Fleischmann, R. D., M. D. Adams, O. White, R. A. Clayton, E. F. Kirkness, A. R. Kerlavage, C. J. Bult, J. F. Tomb, B. A. Dougherty, J. M. Merrick, K. McKenney, G. Sutton, W. FitzHugh, C. Fields, J. D. Gocayne, J. Scott, R. Shirley, L. Liu, A. Glodek, J. M. Kelley, J. F. Weidman, C. A. Phillips, T. Spriggs, E. Hedblom, M. D. Cotton, T. R. Utterback, M. C. Hanna, D. T. Nguyen, D. M. Saudek, R. C. Brandon, L. D. Fine, J. L. Fritchman, J. L. Fuhrmann, N. S. M. Geoghagen, C. L. Gnehm, L. A. McDonald, K. V. Small, C. M. Fraser, H. O. Smith, and J. C. Venter. 1995. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269:496-512.[Abstract/Free Full Text]
4
4. Fluit, A. C., A. Florijn, J. Verhoef, and D. Milatovic. 2005. Susceptibility of European ß-lactamase-positive and -negative Haemophilus influenzae isolates from the periods 1997/1998 and 2002/2003. J. Antimicrob. Chemother. 56:133-138.[Abstract/Free Full Text]
5
5. Hasegawa, K., N. Chiba, R. Kobayashi, S. Y. Murayama, S. Iwata, K. Sunakawa, and K. Ubukata. 2004. Rapidly increasing prevalence of ß-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis. Antimicrob. Agents Chemother. 48:1509-1514.[Abstract/Free Full Text]
6
6. Hasegawa, K., K. Yamamoto, N. Chiba, R. Kobayashi, K. Nagai, M. R. Jacobs, P. C. Appelbaum, K. Sunakawa, and K. Ubukata. 2003. Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb. Drug Resist. 9:39-46.[Medline]
7
7. Hiltke, T. J., A. T. Schiffmacher, A. J. Dagonese, S. Sethi, and T. F. Murphy. 2003. Horizontal transfer of the gene encoding outer membrane protein P2 of nontypeable Haemophilus influenzae, in a patient with chronic obstructive pulmonary disease. J. Infect. Dis. 188:114-117.[CrossRef][Medline]
8
8. Hoban, D., and D. Felmingham. 2002. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J. Antimicrob. Chemother. 50(Suppl. 1):49-59.[Abstract]
9
9. Jacobs, M. R., D. Felmingham, P. C. Appelbaum, R. N. Gruneberg, and the Alexander Project Group. 2003. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52:229-246.[Abstract/Free Full Text]
10
10. Karlowsky, J. A., G. Verma, G. G. Zhanel, and D. J. Hoban. 2000. Presence of ROB-1 ß-lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae. J. Antimicrob. Chemother. 45:871-875.[Abstract/Free Full Text]
11
11. Konno, M., K. Ubukata, N. Chiba, K. Hasegawa, Y. Shibasaki, K. Sudo, K. Kishibe, H. Hujikawa, M. Sakai, Y. Koyama, M. Yokota, and T. Mayama. 2001. Postmarketing special investigation and its verification of precision for cefditoren pivoxil. Jpn. J. Chemother. 49:369-396. (In Japanese.)
12
12. Matic, V., B. Bozdogan, M. R. Jacobs, K. Ubukata, and P. C. Appelbaum. 2003. Contribution of ß-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in ß-lactamases-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae. J. Antimicrob. Chemother. 52:1018-1021.[Abstract/Free Full Text]
13
13. Medeiros, A. A., R. Levesque, and G. A. Jacoby. 1986. An animal source for the ROB-1 ß-lactamase of Haemophilus influenzae type B. Antimicrob. Agents Chemother. 29:212-215.[Abstract/Free Full Text]
14
14. National Committee for Clinical Laboratory Standards. 2002. Methods for dilution antimicrobial susceptibility for bacteria that grow aerobically; approved standard, 5th ed. NCCLS document M7-A5, vol. 20, no. 2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15
15. Nazir, J., C. Urban, N. Mariano, J. Burns, B. Tommasulo, C. Rosenberg, S. Segal-Maurer, and J. J. Rahal. 2004. Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology. Clin. Infect. Dis. 38:1564-1569.[CrossRef][Medline]
16
16. Osaki, Y., Y. Sanbongi, M. Ishikawa, H. Kataoka, T. Suzuki, K. Maeda, and T. Ida. 2005. Genetic approach to study the relationship between penicillin-binding protein 3 mutations and Haemophilus influenzae ß-lactam resistance by using site-directed mutagenesis and gene recombinants. Antimicrob. Agents Chemother. 49:2834-2839.[Abstract/Free Full Text]
17
17. Scriver, S. R., S. L. Walmsley, C. L. Kau, D. J. Hoban, J. Brunton, A. McGeer, T. C. Moore, E. Witwicki, the Canadian Haemophilus Study Group, and D. E. Low. 1994. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their ß-lactamases. Antimicrob. Agents Chemother. 38:1678-1680.[Abstract/Free Full Text]
18
18. Seki, H., Y. Kasahara, K. Ohta, Y. Saikawa, R. Sumita, A. Yachie, S. Fujita, and S. Koizumi. 1999. Increasing prevalence of ampicillin-resistant non-ß-lactamase-producing strains of Haemophilus influenzae in children in Japan. Chemotherapy 45:15-21.[Medline]
19
19. Smith-Vaughan, H. C., K. S. Sriprakash, J. D Mathews, and D. J. Kemp. 1997. Nonencapsulated Haemophilus influenzae in Aboriginal infants with otitis media: prolonged carriage of P2 porin variants and evidence for horizontal P2 gene transfer. Infect. Immun. 65:1468-1474.[Abstract]
20
20. Straker, K., M. Wootton, A. M. Simm, P. M. Bennett, A. P. MacGowan, and T. R. Walsh. 2003. Cefuroxime resistance in non-ß-lactamase Haemophilus influenzae is linked to mutations in ftsI. J. Antimicrob. Chemother. 51:523-530.[Abstract/Free Full Text]
21
21. Suzuki, K., T. Nishimura, and S. Baba. 2003. Current status of bacterial resistance in the otolaryngology field: results from the second nationwide survey in Japan. J. Infect. Chemother. 9:46-62.[CrossRef][Medline]
22
22. Ubukata, K. 2003. Problems associated with high prevalence of multidrug-resistant bacteria in patients with community-acquired infections. J. Infect. Chemother. 9:285-291.[CrossRef][Medline]
23
23. Ubukata, K., Y. Shibasaki, K. Yamamoto, N. Chiba, K. Hasegawa, Y. Takeuchi, K. Sunakawa, M. Inoue, and M. Konno. 2001. Association of amino acid substitutions in penicillin-binding protein 3 with ß-lactam resistance in ß-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob. Agents Chemother. 45:1693-1699.[Abstract/Free Full Text]
24
24. Vega, R., H. L. Sadoff, and M. J. Patterson. 1976. Mechanism of ampicillin resistance in Haemophilus influenzae type B. Antimicrob. Agents Chemother. 9:164-168.[Abstract/Free Full Text]
25
25. Yoshida, I., G. Sugimori, I. Higashiyama, Y. Kimura, and Y. Yamano. 2003. Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial agents. Jpn. J. Chemother. 51:209-232. (In Japanese.)

---

Antimicrobial Agents and Chemotherapy, July 2006, p. 2487-2492, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.01316-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Nakamura, S., Yanagihara, K., Morinaga, Y., Izumikawa, K., Seki, M., Kakeya, H., Yamamoto, Y., Kamihira, S., Kohno, S. (2009). Melting Curve Analysis for Rapid Detection of Topoisomerase Gene Mutations in Haemophilus influenzae. J. Clin. Microbiol. 47: 781-784 [Abstract] [Full Text]  
• Garcia-Cobos, S., Campos, J., Cercenado, E., Roman, F., Lazaro, E., Perez-Vazquez, M., de Abajo, F., Oteo, J. (2008). Antibiotic Resistance in Haemophilus influenzae Decreased, except for {beta}-Lactamase-Negative Amoxicillin-Resistant Isolates, in Parallel with Community Antibiotic Consumption in Spain from 1997 to 2007. Antimicrob. Agents Chemother. 52: 2760-2766 [Abstract] [Full Text]  
• Garcia-Cobos, S., Campos, J., Roman, F., Carrera, C., Perez-Vazquez, M., Aracil, B., Oteo, J. (2008). Low {beta}-Lactamase-Negative Ampicillin-Resistant Haemophilus influenzae Strains Are Best Detected by Testing Amoxicillin Susceptibility by the Broth Microdilution Method. Antimicrob. Agents Chemother. 52: 2407-2414 [Abstract] [Full Text]  
• Takahata, S., Kato, Y., Sanbongi, Y., Maebashi, K., Ida, T. (2008). Comparison of the Efficacies of Oral {beta}-Lactams in Selection of Haemophilus influenzae Transformants with Mutated ftsI Genes. Antimicrob. Agents Chemother. 52: 1880-1883 [Abstract] [Full Text]  
• Hotomi, M., Fujihara, K., Billal, D. S., Suzuki, K., Nishimura, T., Baba, S., Yamanaka, N. (2007). Genetic Characteristics and Clonal Dissemination of {beta}-Lactamase-Negative Ampicillin-Resistant Haemophilus influenzae Strains Isolated from the Upper Respiratory Tract of Patients in Japan. Antimicrob. Agents Chemother. 51: 3969-3976 [Abstract] [Full Text]  
• Billal, D. S., Hotomi, M., Yamanaka, N. (2007). Can the Etest Correctly Determine the MICs of {beta}-Lactam and Cephalosporin Antibiotics for Beta-Lactamase-Negative Ampicillin-Resistant Haemophilus influenzae?. Antimicrob. Agents Chemother. 51: 3463-3464 [Full Text]  
• Cerquetti, M., Giufre, M., Cardines, R., Mastrantonio, P. (2007). First Characterization of Heterogeneous Resistance to Imipenem in Invasive Nontypeable Haemophilus influenzae Isolates. Antimicrob. Agents Chemother. 51: 3155-3161 [Abstract] [Full Text]  
• Garcia-Cobos, S., Campos, J., Lazaro, E., Roman, F., Cercenado, E., Garcia-Rey, C., Perez-Vazquez, M., Oteo, J., de Abajo, F. (2007). Ampicillin-Resistant Non-{beta}-Lactamase-Producing Haemophilus influenzae in Spain: Recent Emergence of Clonal Isolates with Increased Resistance to Cefotaxime and Cefixime. Antimicrob. Agents Chemother. 51: 2564-2573 [Abstract] [Full Text]  
• Stone, K. C., Dagan, R., Arguedas, A., Leibovitz, E., Wang, E., Echols, R. M., Janjic, N., Critchley, I. A. (2007). Activity of Faropenem against Middle Ear Fluid Pathogens from Children with Acute Otitis Media in Costa Rica and Israel. Antimicrob. Agents Chemother. 51: 2230-2235 [Abstract] [Full Text]  
• Takahata, S., Ida, T., Senju, N., Sanbongi, Y., Miyata, A., Maebashi, K., Hoshiko, S. (2007). Horizontal Gene Transfer of ftsI, Encoding Penicillin-Binding Protein 3, in Haemophilus influenzae. Antimicrob. Agents Chemother. 51: 1589-1595 [Abstract] [Full Text]  
• Tristram, S., Jacobs, M. R., Appelbaum, P. C. (2007). Antimicrobial Resistance in Haemophilus influenzae. Clin. Microbiol. Rev. 20: 368-389 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanbongi, Y. Articles by Ubukata, K. Search for Related Content PubMed PubMed Citation Articles by Sanbongi, Y. Articles by Ubukata, K.